ArticleFrontiers in endocrinology2022
Effect of
Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
- Significance of pathological changes and chemokine expression in various organs in a Graves' disease animal model.Journal of molecular histology · 2025Article
- Treatment of patients with hyperthyroidism and liver failure: a retrospective cohort study.BMC gastroenterology · 2025Article
- The evolution and hotspots of radioactive iodine therapy in hyperthyroidism: a bibliometric analysis.Nuclear medicine communications · 2025Review
- Subacute liver failure caused by hyperthyroidism and complicated by drugs: a case report and review of the literature.Frontiers in medicine · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Treatment decision-making in Graves' disease (GD) with severe liver dysfunction (LD) is a clinical challenge. This research was carried out to evaluate the effect of radioiodine ( Methods: In total, 45 patients diagnosed with GD and severe LD were enrolled and allocated to two groups: patients treated with Results: Thyroid hormone concentrations were lower 2 weeks after Conclusion: The key point of treating GD patients with severe LD is to control the GD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.